CONMED Corporation

NYSE:CNMD Stock Report

Market Cap: US$2.2b

CONMED Valuation

Is CNMD undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of CNMD when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: CNMD ($69.32) is trading below our estimate of fair value ($134.52)

Significantly Below Fair Value: CNMD is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for CNMD?

Key metric: As CNMD is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for CNMD. This is calculated by dividing CNMD's market cap by their current earnings.
What is CNMD's PE Ratio?
PE Ratio16.3x
EarningsUS$131.74m
Market CapUS$2.20b

Price to Earnings Ratio vs Peers

How does CNMD's PE Ratio compare to its peers?

The above table shows the PE ratio for CNMD vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average60.3x
LMAT LeMaitre Vascular
49.2x12.2%US$2.0b
NUVA NuVasive
73.3x46.2%US$2.1b
LIVN LivaNova
109.1x48.2%US$2.7b
INMD InMode
9.4x7.5%US$1.5b
CNMD CONMED
16.3x13.8%US$2.2b

Price-To-Earnings vs Peers: CNMD is good value based on its Price-To-Earnings Ratio (16.3x) compared to the peer average (55.9x).

Price to Earnings Ratio vs Industry

How does CNMD's PE Ratio compare vs other companies in the US Medical Equipment Industry?

4 CompaniesPrice / EarningsEstimated GrowthMarket Cap
BDMD Baird Medical Investment Holdings
4.4xn/aUS$54.03m
MHUA Meihua International Medical Technologies
0.8xn/aUS$12.80m
PAVM PAVmed
0.5x-90.0%US$7.47m
RTSL Rapid Therapeutic Science Laboratories
0.3xn/aUS$18.99k
No more companies available in this PE range
CNMD 16.3xIndustry Avg. 34.4xNo. of Companies8PE020406080100+
4 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: CNMD is good value based on its Price-To-Earnings Ratio (16.3x) compared to the US Medical Equipment industry average (36x).

Price to Earnings Ratio vs Fair Ratio

What is CNMD's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

CNMD PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio16.3x
Fair PE Ratio27.1x

Price-To-Earnings vs Fair Ratio: CNMD is good value based on its Price-To-Earnings Ratio (16.3x) compared to the estimated Fair Price-To-Earnings Ratio (27.1x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst CNMD forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$69.32
US$81.14
+17.1%
9.9%US$97.00US$72.00n/a7
Dec ’25US$74.04
US$83.13
+12.3%
12.4%US$102.00US$72.00n/a8
Nov ’25US$70.40
US$83.13
+18.1%
12.4%US$102.00US$72.00n/a8
Oct ’25US$68.28
US$82.00
+20.1%
13.6%US$102.00US$70.00n/a8
Sep ’25US$73.22
US$82.00
+12.0%
13.6%US$102.00US$70.00n/a8
Aug ’25US$65.34
US$82.00
+25.5%
13.6%US$102.00US$70.00n/a8
Jul ’25US$66.99
US$92.38
+37.9%
19.3%US$132.00US$75.00n/a8
Jun ’25US$76.44
US$92.38
+20.8%
19.3%US$132.00US$75.00n/a8
May ’25US$68.34
US$92.38
+35.2%
19.3%US$132.00US$75.00n/a8
Apr ’25US$78.97
US$111.13
+40.7%
11.2%US$132.00US$98.00n/a8
Mar ’25US$79.95
US$111.13
+39.0%
11.2%US$132.00US$98.00n/a8
Feb ’25US$83.76
US$111.13
+32.7%
11.2%US$132.00US$98.00n/a8
Jan ’25US$109.51
US$123.38
+12.7%
9.2%US$142.00US$107.00n/a8
Dec ’24US$109.62
US$123.38
+12.5%
9.2%US$142.00US$107.00US$74.048
Nov ’24US$98.72
US$123.38
+25.0%
9.2%US$142.00US$107.00US$70.408
Oct ’24US$100.85
US$136.38
+35.2%
5.8%US$145.00US$123.00US$68.288
Sep ’24US$110.48
US$136.89
+23.9%
5.6%US$145.00US$123.00US$73.229
Aug ’24US$118.20
US$136.89
+15.8%
5.6%US$145.00US$123.00US$65.349
Jul ’24US$135.89
US$128.00
-5.8%
5.8%US$140.00US$119.00US$66.999
Jun ’24US$123.79
US$127.56
+3.0%
5.4%US$140.00US$119.00US$76.449
May ’24US$125.85
US$126.00
+0.1%
4.4%US$135.00US$119.00US$68.348
Apr ’24US$103.86
US$111.63
+7.5%
8.7%US$124.00US$96.00US$78.978
Mar ’24US$96.16
US$112.17
+16.6%
6.9%US$122.00US$100.00US$79.956
Feb ’24US$99.29
US$100.50
+1.2%
8.4%US$108.00US$83.00US$83.766
Jan ’24US$88.64
US$100.50
+13.4%
8.4%US$108.00US$83.00US$109.516
Dec ’23US$87.46
US$98.50
+12.6%
8.4%US$108.00US$83.00US$109.626

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/18 06:53
End of Day Share Price 2024/12/18 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

CONMED Corporation is covered by 14 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Travis SteedBarclays
Travis SteedBofA Global Research
Kristen StewartCL King & Associates, Inc.